---
title: "Paxlovid (nirmatrelvir; ritonavir) in COVID-19: Safety questions"
description: "Safety questions on Paxlovid (nirmatrelvir; ritonavir) in COVID-19, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects. Questions: How many patients stopped Paxlovid because of side effects (EPIC-HR)? Does COVID-19 rebound happen after Paxlovid? Is Paxlovid rebound linked to hospitalization or death? 3 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/paxlovid--covid-19/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Paxlovid (nirmatrelvir; ritonavir) in COVID-19: Safety questions

Manufacturer: Pfizer Inc  
Prescribing information: [Paxlovid](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599)

Safety questions that apply to every indication of Paxlovid are on [Paxlovid (nirmatrelvir; ritonavir), all indications: Safety](https://www.evicenter.com/medical-information/paxlovid/safety).

## Side effects

<a id="paxlovid-stopped-for-side-effects"></a>

### How many patients stopped Paxlovid because of side effects (EPIC-HR)?

> “The proportions of subjects who discontinued treatment due to an adverse event were 2.0% in the PAXLOVID group and 4.2% in the placebo group.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=The%20proportions%20of%20subjects%20who,4.2%25%20in%20the%20placebo%20group.)

## Safety

<a id="paxlovid-viral-rebound"></a>

### Does COVID-19 rebound happen after Paxlovid?

> “EPIC-HR was not designed to evaluate COVID-19 rebound; however, exploratory analyses were conducted to assess the relationship between PAXLOVID use and rebound in viral RNA shedding levels.<sup>1</sup>
>
> Post-treatment increases in SARS-CoV-2 RNA shedding levels (ie, viral RNA rebound) in nasopharyngeal samples were observed on day 10 and/or day 14 in a subset of PAXLOVID and placebo recipients in EPIC-HR, irrespective of COVID-19 symptoms.<sup>1</sup>”

Source: [PAXLOVID: Viral Rebound, captured 2026-11-13](https://paxlovid.pfizerpro.com/safety/viral-rebound#:~:text=EPIC%2DHR%20was%20not%20designed%20to,in%20EPIC%2DHR%2C%20irrespective%20of%20COVID%2D19)

> “The frequency of detection of post-treatment viral RNA rebound varied according to analysis parameters but was generally similar among PAXLOVID and placebo recipients.<sup>1</sup>”

Source: [PAXLOVID: Viral Rebound, captured 2026-11-13](https://paxlovid.pfizerpro.com/safety/viral-rebound#:~:text=The%20frequency%20of%20detection%20of,similar%20among%20PAXLOVID%20and%20placebo)

> “Alternative definitions of viral rebound are used in various studies, including different criteria for what constitutes viral rebound and/or different sampling time points and methods used to determine VL. Additionally, although there may be some overlap, symptom rebound and viral rebound may often be defined differently within studies”

Source: [PAXLOVID: Viral Rebound, captured 2026-11-13](https://paxlovid.pfizerpro.com/safety/viral-rebound#:~:text=Alternative%20definitions%20of%20viral%20rebound,be%20defined%20differently%20within%20studies)

<a id="paxlovid-rebound-hospitalization"></a>

### Is Paxlovid rebound linked to hospitalization or death?

> “EPIC-HR and EPIC-SR were not designed to evaluate COVID-19 rebound; exploratory analyses were conducted to assess the relationship between PAXLOVID use and rebound in viral RNA shedding levels.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=EPIC%2DHR%20and%20EPIC%2DSR%20were%20not,in%20viral%20RNA%20shedding%20levels.)

> “Post-treatment viral RNA rebound was not associated with the primary clinical outcome of COVID-19 related hospitalization or death from any cause through Day 28 following the single 5-day course of PAXLOVID treatment. The clinical relevance of post-treatment increases in viral RNA following PAXLOVID or placebo treatment is unknown.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Post%2Dtreatment%20viral%20RNA%20rebound%20was,or%20placebo%20treatment%20is%20unknown.)

## Related pages
- [Medical information: Paxlovid (nirmatrelvir; ritonavir): COVID-19](https://www.evicenter.com/medical-information/paxlovid--covid-19)
- [Indication](https://www.evicenter.com/medical-information/paxlovid--covid-19/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/paxlovid--covid-19/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/paxlovid--covid-19/real-world-evidence)
- [Specific populations](https://www.evicenter.com/medical-information/paxlovid--covid-19/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/paxlovid--covid-19/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/paxlovid--covid-19/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/paxlovid--covid-19/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/paxlovid--covid-19/guidelines)
